+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Stimulation of endothelin B receptors by IRL-1620 decreases the progression of Alzheimer's disease



Stimulation of endothelin B receptors by IRL-1620 decreases the progression of Alzheimer's disease



Neuroscience 301: 1-11



Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by severe cognitive impairment that ultimately leads to death. Endothelin (ET) and its receptors have been considered as therapeutic targets for AD. Recent studies in our lab have shown that stimulation of ETB receptors provide significant neuroprotection following Aβ1-40 administration. It is possible that IRL-1620 may be neuroprotective due to angiogenesis. However, the effect of IRL-1620 on neurovascular remodeling following Aβ1-40 administration has not been established. The purpose of this study was to determine the effect of stimulation of ETB receptors by IRL-1620 on vascular and neuronal growth factors after Aβ1-40 administration. Rats were treated with Aβ1-40 (day 1, 7 and 14) in the lateral cerebral ventricles using stereotaxically implanted cannula and received three intravenous injections of IRL-1620 (an ETB agonist), and/or BQ788 (an ETB antagonist) at 2-h interval on day 8; experiments were performed on day 15. Rats were sacrificed for estimation of brain ETB receptors, vascular endothelial growth factor (VEGF) and nerve growth factor (NGF) expression using immunofluorescence and Western blot. In the Morris swim task, amyloid-β (Aβ)-treated rats showed a significant (p<0.0001) impairment in spatial memory. Rats treated with IRL-1620 significantly (p<0.001) reduced the cognitive impairment induced by Aβ. BQ788 treatment completely blocked IRL-1620-induced improvement in cognitive impairment. IRL-1620 treatment enhanced the number of blood vessels labeled with VEGF compared to vehicle treatment. Additionally, cells showed increased (p<0.001) positive staining for NGF in IRL-1620-treated animals. ETB, VEGF and NGF protein expression significantly (p<0.001) increased in the brain of IRL-1620-treated rats as compared to vehicle. Pretreatment with BQ788 blocked the effects of IRL-1620, thus confirming the role of ETB receptors in the neurovascular remodeling actions of IRL-1620. Results of the present study demonstrate that IRL-1620 improves both acquisition (learning) and retention (memory) on the water maze task and enhances angiogenic and neurogenic remodeling. These findings indicate that the ETB receptor may be a novel therapeutic target for AD and other neurovascular degenerative disorders.

(PDF emailed within 0-6 h: $19.90)

Accession: 058905922

Download citation: RISBibTeXText

PMID: 26022359

DOI: 10.1016/j.neuroscience.2015.05.044


Related references

Suc- -endothelin-1 , IRL 1620, identifies two populations of ETB receptors in guinea-pig bronchus. British Journal of Pharmacology 127(6): 1406-1414, 1999

Intraportal nicotine infusion in rats decreases hepatic blood flow through endothelin-1 and both endothelin A and endothelin B receptors. Toxicology and Applied Pharmacology 196(1): 1-10, 2004

Intraportal nicotine infusion usion in rats decreases hepatic blood flow through endothelin-1 and both endothelin A and endothelin B receptors. Toxicology & Applied Pharmacology 196(1): 1-10, April 1, 2004

Cognitive stimulation therapy for Alzheimer's disease: the effect of cognitive stimulation therapy on the progression of mild Alzheimer's disease in patients treated with donepezil. International Psychogeriatrics 19(2): 241-252, 2006

Species differences in the binding characteristics of [125I]IRL-1620, a potent agonist specific for endothelin-B receptors. Journal of Pharmacology and Experimental Therapeutics 268(1): 202-207, 1994

Stimulation of endothelin B receptor with IRL 1620 leads to endothelium-dependent increase in cyclic GMP via nitric oxide formation in rat aorta. Japanese Journal of Pharmacology 61(SUPPL 1): 86P, 1993

Characterization of ET-B receptors mediating contractions induced by endothelin-1 or IRL 1620 in guinea-pig isolated airways: Effects of BQ-123, FR139317 or PD 145065. British Journal of Pharmacology 111(4): 1009-1016, 1994

The Expression of MicroRNA miR-107 Decreases Early in Alzheimer's Disease and May Accelerate Disease Progression through Regulation of b-Site Amyloid Precursor Protein-Cleaving Enzyme 1. 2008

The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. Journal of Neuroscience 28(5): 1213-1223, 2008

Distribution of two subtypes of endothelin receptors in rat tissues assessed by quantitative autoradiography with iodine-125 ET-1 and iodine-125 IRL 1620. Japanese Journal of Pharmacology 61(SUPPL 1): 256P, 1993

Circulating levels of IL-1 family cytokines and receptors in Alzheimer's disease: new markers of disease progression?. Journal of Neuroinflammation 15(1): 342-342, 2018

Effects of endothelin receptor selective antagonists, BQ-123 and BQ-788, on IRL 1620 and endothelin-1 responses of airway and vascular preparations from rats. Pulmonary Pharmacology. 8(1): 11-19, 1995

Study on the role of endothelin and its receptors on progression of pulmonary hypertension in patients with mixed connective tissue disease. Arthritis & Rheumatism 40(9 SUPPL ): S297, Sept, 1997

Changes in Plasma β-NGF and Its Receptors Expression on Peripheral Blood Monocytes During Alzheimer's Disease Progression. Journal of Alzheimer's Disease 55(3): 1005-1017, 2016

Endothelin-1 induces gene expression through stimulation of endothelin type A receptors in normal rat kidney cells. Journal of Cellular Physiology 164(3): 491-498, 1995